Molecular Docking Simulation Studies of Curcumin and Its Derivatives as Cyclin-Dependent Kinase 2 Inhibitors
- 28 August 2020
- journal article
- research article
- Published by Galenos Yayinevi in Turkish Journal of Pharmaceutical Sciences
- Vol. 17 (4) , 417-423
Abstract
Cyclin-dependent kinase 2 (CDK2) is a protein that plays a role in regulating the cell cycle and its overexpression contributes to uncontrolled cell proliferation. Inhibition of CDK2 is known to be a mechanism of action of various anti-cancer drugs. Curcumin is an active compound of Curcuma longa and it has been reported to inhibit the activity of cyclin D, cyclin E, CDK2, CDK4, and CDK6. This study aimed to design more active curcumin derivatives as anticancer drugs by targeting CDK2 through a molecular modeling approach. The molecular modeling approach consists of receptor and ligand preparation, method validation, pharmacophore modeling, and docking simulation. The results of the molecular docking simulation show that the free bonding energy (ΔG) of curcumin and kurkumod 23 and 24 (the best modification of curcumin) are -7.80, -9.15, and -9.36 kcal/mol, respectively. The hydrogen interaction between kurkumod 23 and 24 with CDK occurred on Lys33 residue, which is considered a potential interaction site for CDK2 inhibitor compounds. Pharmacophore modeling showed that kurkumod 23 and 24 have pharmacophore-fit values of 45.20% and 47.26%, respectively. The results of this study indicate that kurkumod 23 and 24 are the best and most potent modifications of curcumin as CDK2 antagonist, based on the interactions that occur between these two derivatives with amino acid residues from the CDK2 receptor.Keywords
This publication has 7 references indexed in Scilit:
- Design, Synthesis, Anticancer Evaluation and Docking Studies of Novel Heterocyclic Derivatives Obtained via Reactions Involving CurcuminMolecules, 2018
- Pharmacophore modeling and in silico toxicity assessment of potential anticancer agents from African medicinal plantsDrug Design, Development and Therapy, 2016
- Molecular docking as a popular tool in drug design, an in silico travelAdvances and Applications in Bioinformatics and Chemistry, 2016
- Protein-Protein Docking: From Interaction to InteractomeBiophysical Journal, 2014
- Curcumin and curcuminoids in quest for medicinal status.Acta Biochimica Polonica, 2012
- Lead- and drug-like compounds: the rule-of-five revolutionDrug Discovery Today: Technologies, 2004
- Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2): Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic AnalysisJournal of Medicinal Chemistry, 2001